oh, think I got it.. single agent (Bisantrene) v combo & larger patient group in new trial
from Stategic update
..
Prof Nagler led the Phase II single agent open label r/r AML trial of Bisantrene which reported
a 40% clinical response rate in a very difficult to treat population of r/r AML patients (ASX
announcement: 16 June 2020).
This Phase I/II trial will enrol 29 patients and involve the use of Bisantrene in combination with
the nucleoside analogues, clofarabine and fludarabine. Unpublished preclinical data from
Professors Andersson and Valdez of the MD Anderson Cancer Clinic in Houston, Texas has
identified strong synergistic killing of AML cells using this three-drug combination.
Guess there'll be some dose discovery (PI) work in the trial.
oh, think I got it.. single agent (Bisantrene) v combo & larger...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.035(2.18%) |
Mkt cap ! $266.3M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.56 | $101.6K | 64.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7451 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 408 | 1 |
View Market Depth
| Last trade - 15.53pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.58 |
Change
-0.035 ( 1.25 %) |
||||
| Open | High | Low | Volume | ||
| $1.58 | $1.62 | $1.56 | 7255 | ||
| Last updated 15.57pm 05/06/2024 ? | |||||
| RAC (ASX) Chart |